Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.69 |
| ▸ | FPR2 | P25090 | 10/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.51 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25008453 | 0.88 | AAK1 (0.57) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL31433059 | 0.88 | AAK1 (0.57) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL9490468 | 0.88 | AAK1 (0.62) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL9610763 | 0.87 | CTSK (0.59) | AAK1EGFRCTSSCTSKCTSL | |
| SCHEMBL9609480 | 0.87 | CTSK (0.59) | AAK1EGFRCTSSCTSKCTSL | |
| SCHEMBL21643188 | 0.86 | AAK1 (0.55) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL4423023 | 0.86 | AAK1 (0.55) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL30135004 | 0.86 | CTSS (0.52) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL30134835 | 0.86 | CTSS (0.52) | AAK1FPR2EGFRCTSSCTSK | |
| SCHEMBL31064845 | 0.85 | AAK1 (0.54) | AAK1FPR2EGFRCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | AAK1 436/4885FPR2 4605/4885EGFR 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.